Testing
M IDH2
Targeted next generation sequencing is performed to asses for the following pathogenic hotspot mutations: IDH2 p.R140 and IDH2p.R172. IDH2 Mutation Analysis
Learn more
M IDH1
Targeted next generation sequencing is performed to asses for the following pathogenic hotspot mutations: IDH1 p.R132 IDH1 Mutation Analysis
Learn more
FP IGH MYC
The t(8;14)(q32;q24) joins the cellular oncogenes C-MYC with sequences from immunoglobulin heavy chain gene enhancers leading to deregulated expression of C-MYC protein. This abnormality is characteristic of Burkitt lymphoma and… IGH/MYC t(8;14)*, paraffin
Learn more
Rearrangements involving the IGH gene have been identified in about 50% of non-Hodgkin B-cell lymphomas (NHLs) and correlated to clinically relevant subgroups. A t(14;18)(q32;q21) is found in 88.1% of follicular…
Learn more
Learn more
FP IGH MALT1
Translocation (11;18)(q21;q21) has been associated with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). Translocation (11;18) leads to the fusion of the apoptosis inhibitor-2 (API2) gene and… IGH/MALT1 t(14;18), paraffin
Learn more
FP BCL2
BCL2 blocks apoptosis and maintains long-term immune responsiveness including B-cell memory. The most frequent non-random chromosome rearrangement in non-Hodgkin lymphoma (NHL) of B-cell type is t(14;18)(q32;q21), which is found in… IGH/BCL2 t(14;18), paraffin
Learn more
Mantle cell lymphoma can be difficult to distinguish morphologically from other B-cell malignant lymphomas. The translocation probe is designed to detect the juxtaposition of the IGH locus (14q32) next to…
Learn more
Learn more
M IDH1/2
Targeted next generation sequencing is performed to asses for the following pathogenic hotspot mutations: IDH1 p.R132 and IDH2 p.R140 and IDH2p.R172. IDH1 and IDH2 Mutation Analysis
Learn more
CLL/SLL is the most common leukemia diagnosed among adults in Western countries and is associated with heterogeneous clinical outcomes. IgVH somatic hypermutation (SHM) status is a primary component of the…
Learn more
Learn more
F IGH MALT1
Translocation (11;18)(q21;q21) has been associated with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). Translocation (11;18) leads to the fusion of the apoptosis inhibitor-2 (API2) gene and… IGH/MALT1 t(14;18)
Learn more
F IGH MAF
The t(14;16)(q32;q23) is detectable in 2–10% of patients with plasma cell myeloma and in about 25% of myeloma cell lines. The t(14;16)(q32;q23) is difficult to detect by conventional karyotypes. Although… IGH/MAF t(14;16)
Learn more
Rearrangements involving the IGH gene have been identified in about 50% of non-Hodgkin B-cell lymphomas (NHLs) and correlated to clinically relevant subgroups. A t(14;18)(q32;q21) is found in 88.1% of follicular…
Learn more
Learn more
F FGFR3
The t(4;14) translocation is found in approximately 10% of myeloma patients and results in the deregulation of at least two genes, MMSET and fibroblast growth factor receptor 3 (FGFR3), with… IGH/FGFR3 t(4;14)
Learn more
F IGH MYC
The t(8;14)(q32;q24) joins the cellular oncogenes C-MYC with sequences from immunoglobulin heavy chain gene enhancers leading to deregulated expression of C-MYC protein. This abnormality is characteristic of Burkitt lymphoma and… IGH/MYC t(8;14)*
Learn more
